Literature DB >> 23160323

Targeting ALK, ROS1, and BRAF kinases.

Robert C Doebele1, D Ross Camidge.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23160323      PMCID： PMC4155403          DOI： 10.1097/JTO.0b013e31826df05e

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  10 in total

1.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Authors:  Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

2.  Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.

Authors:  Ryohei Katayama; Alice T Shaw; Tahsin M Khan; Mari Mino-Kenudson; Benjamin J Solomon; Balazs Halmos; Nicholas A Jessop; John C Wain; Alan Tien Yeo; Cyril Benes; Lisa Drew; Jamal Carlos Saeh; Katherine Crosby; Lecia V Sequist; A John Iafrate; Jeffrey A Engelman
Journal:  Sci Transl Med       Date:  2012-01-25       Impact factor: 17.956

3.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

Authors:  Anirudh Prahallad; Chong Sun; Sidong Huang; Federica Di Nicolantonio; Ramon Salazar; Davide Zecchin; Roderick L Beijersbergen; Alberto Bardelli; René Bernards
Journal:  Nature       Date:  2012-01-26       Impact factor: 49.962

4.  EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.

Authors:  Jussi P Koivunen; Craig Mermel; Kreshnik Zejnullahu; Carly Murphy; Eugene Lifshits; Alison J Holmes; Hwan Geun Choi; Jhingook Kim; Derek Chiang; Roman Thomas; Jinseon Lee; William G Richards; David J Sugarbaker; Christopher Ducko; Neal Lindeman; J Paul Marcoux; Jeffrey A Engelman; Nathanael S Gray; Charles Lee; Matthew Meyerson; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

5.  Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.

Authors:  Paul K Paik; Maria E Arcila; Michael Fara; Camelia S Sima; Vincent A Miller; Mark G Kris; Marc Ladanyi; Gregory J Riely
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

6.  ROS1 rearrangements define a unique molecular class of lung cancers.

Authors:  Kristin Bergethon; Alice T Shaw; Sai-Hong Ignatius Ou; Ryohei Katayama; Christine M Lovly; Nerina T McDonald; Pierre P Massion; Christina Siwak-Tapp; Adriana Gonzalez; Rong Fang; Eugene J Mark; Julie M Batten; Haiquan Chen; Keith D Wilner; Eunice L Kwak; Jeffrey W Clark; David P Carbone; Hongbin Ji; Jeffrey A Engelman; Mari Mino-Kenudson; William Pao; A John Iafrate
Journal:  J Clin Oncol       Date:  2012-01-03       Impact factor: 44.544

7.  Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

Authors:  Robert C Doebele; Amanda B Pilling; Dara L Aisner; Tatiana G Kutateladze; Anh T Le; Andrew J Weickhardt; Kimi L Kondo; Derek J Linderman; Lynn E Heasley; Wilbur A Franklin; Marileila Varella-Garcia; D Ross Camidge
Journal:  Clin Cancer Res       Date:  2012-01-10       Impact factor: 12.531

8.  Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.

Authors:  Kurtis D Davies; Anh T Le; Mariana F Theodoro; Margaret C Skokan; Dara L Aisner; Eamon M Berge; Luigi M Terracciano; Federico Cappuzzo; Matteo Incarbone; Massimo Roncalli; Marco Alloisio; Armando Santoro; D Ross Camidge; Marileila Varella-Garcia; Robert C Doebele
Journal:  Clin Cancer Res       Date:  2012-08-23       Impact factor: 12.531

9.  Cancer. Addiction to oncogenes--the Achilles heal of cancer.

Authors:  I Bernard Weinstein
Journal:  Science       Date:  2002-07-05       Impact factor: 47.728

10.  RET, ROS1 and ALK fusions in lung cancer.

Authors:  Kengo Takeuchi; Manabu Soda; Yuki Togashi; Ritsuro Suzuki; Seiji Sakata; Satoko Hatano; Reimi Asaka; Wakako Hamanaka; Hironori Ninomiya; Hirofumi Uehara; Young Lim Choi; Yukitoshi Satoh; Sakae Okumura; Ken Nakagawa; Hiroyuki Mano; Yuichi Ishikawa
Journal:  Nat Med       Date:  2012-02-12       Impact factor: 53.440
  10 in total
  2 in total

Review 1.  ALK and ROS1 as a joint target for the treatment of lung cancer: a review.

Authors:  Raimon Puig de la Bellacasa; Niki Karachaliou; Roger Estrada-Tejedor; Jordi Teixidó; Carlota Costa; José I Borrell
Journal:  Transl Lung Cancer Res       Date:  2013-04

Review 2.  Overview of ALK and ROS1 Rearranged Lung Cancer.

Authors:  Chang Min Choi
Journal:  Tuberc Respir Dis (Seoul)       Date:  2013-12-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.